Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data

Background: Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and to improve symptoms, lung function, and quality of life in randomized controlled trials that included patients with severe eosinophilic uncontrolled asthma (SEUA)...

Descripción completa

Detalles Bibliográficos
Autores: Perez de Llano, Luis Alejandro, García-Cosío, Borja, Astiarraga, Ignacio Lobato, Campos, Gregorio Soto, Alonso, Miguel Angel Tejedor, Malanda, Nuria Marina, Padilla Galo, Alicia, Landa, Isabel Urrutia, de la Rosa, Francisco J. Michel, Garcia-Moguel, Ismael, Reslizumab Real Life
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/23389
Acceso en línea:https://hdl.handle.net/20.500.12105/23389
Access Level:acceso abierto
Palabra clave:Eosinophilic asthma
Reslizumab
Asthma control
Monoclonal antibodies
id ES_db624a64cf6ec0bf901caa59e83c3b8f
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/23389
network_acronym_str ES
network_name_str España
repository_id_str
spelling Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life DataPerez de Llano, Luis AlejandroGarcía-Cosío, BorjaAstiarraga, Ignacio LobatoCampos, Gregorio SotoAlonso, Miguel Angel TejedorMalanda, Nuria MarinaPadilla Galo, AliciaLanda, Isabel Urrutiade la Rosa, Francisco J. MichelGarcia-Moguel, IsmaelReslizumab Real LifeEosinophilic asthmaReslizumabAsthma controlMonoclonal antibodiesBackground: Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and to improve symptoms, lung function, and quality of life in randomized controlled trials that included patients with severe eosinophilic uncontrolled asthma (SEUA) and a history of severe exacerbations. Objective: The aim of the present study was to evaluate the effectiveness of add-on reslizumab in a cohort of patients with SEUA under real-life conditions. Methods: This was a multi-centre, retrospective, real-life study that included subjects with SEUA treated with reslizumab in 44 asthma units throughout Spain. Eligible patients were those who had received at least one dose of reslizumab as part of normal clinical practice. The primary endpoint was complete asthma control at 52 weeks, defined as absence of severe exacerbations, ACT ≥20 and no maintenance oral corticosteroids (OCS). Demographic, clinical, and functional data were collected at baseline (T0), after four to six months (T1); after 12 months (T2) and beyond 12 months of therapy (T3). Results: Treatment with reslizumab achieved complete asthma control in 40% of the 208 included SEUA patients and led to a significant reduction in exacerbations (from 3.0; IQR: 2.0-4.0 at V0 to 0.0; IQR: 0.0-0.0 at V2), maintenance OCS use (from 54.8% (95% CI: 48.0-61.6 at T0 to 18.5% (95% CI: 12.5-24.5 at T2) and a meaningful improvement in symptoms in the entire treated population: ACT increased from 12.8 ± 4.5 at V0 to 20.0 ± 5.1 at V2 (p < 0.001). Most of the improvement achieved at 12 months was obtained at 4-6 months. The retention (continuation) rate of reslizumab was 75% through 2 years (95CI%: 1.9-2.1). Overall, reslizumab showed an adequate safety profile. Conclusion: Reslizumab is an effective therapy for SEUA with adequate safety profile in real-life conditions.Dove Medical Press20242024-10-0420222022-01-0120222022-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttps://hdl.handle.net/20.500.12105/23389reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/233892026-06-12T12:43:37Z
dc.title.none.fl_str_mv Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
title Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
spellingShingle Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
Perez de Llano, Luis Alejandro
Eosinophilic asthma
Reslizumab
Asthma control
Monoclonal antibodies
title_short Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
title_full Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
title_fullStr Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
title_full_unstemmed Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
title_sort Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
dc.creator.none.fl_str_mv Perez de Llano, Luis Alejandro
García-Cosío, Borja
Astiarraga, Ignacio Lobato
Campos, Gregorio Soto
Alonso, Miguel Angel Tejedor
Malanda, Nuria Marina
Padilla Galo, Alicia
Landa, Isabel Urrutia
de la Rosa, Francisco J. Michel
Garcia-Moguel, Ismael
Reslizumab Real Life
author Perez de Llano, Luis Alejandro
author_facet Perez de Llano, Luis Alejandro
García-Cosío, Borja
Astiarraga, Ignacio Lobato
Campos, Gregorio Soto
Alonso, Miguel Angel Tejedor
Malanda, Nuria Marina
Padilla Galo, Alicia
Landa, Isabel Urrutia
de la Rosa, Francisco J. Michel
Garcia-Moguel, Ismael
Reslizumab Real Life
author_role author
author2 García-Cosío, Borja
Astiarraga, Ignacio Lobato
Campos, Gregorio Soto
Alonso, Miguel Angel Tejedor
Malanda, Nuria Marina
Padilla Galo, Alicia
Landa, Isabel Urrutia
de la Rosa, Francisco J. Michel
Garcia-Moguel, Ismael
Reslizumab Real Life
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Eosinophilic asthma
Reslizumab
Asthma control
Monoclonal antibodies
topic Eosinophilic asthma
Reslizumab
Asthma control
Monoclonal antibodies
description Background: Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and to improve symptoms, lung function, and quality of life in randomized controlled trials that included patients with severe eosinophilic uncontrolled asthma (SEUA) and a history of severe exacerbations. Objective: The aim of the present study was to evaluate the effectiveness of add-on reslizumab in a cohort of patients with SEUA under real-life conditions. Methods: This was a multi-centre, retrospective, real-life study that included subjects with SEUA treated with reslizumab in 44 asthma units throughout Spain. Eligible patients were those who had received at least one dose of reslizumab as part of normal clinical practice. The primary endpoint was complete asthma control at 52 weeks, defined as absence of severe exacerbations, ACT ≥20 and no maintenance oral corticosteroids (OCS). Demographic, clinical, and functional data were collected at baseline (T0), after four to six months (T1); after 12 months (T2) and beyond 12 months of therapy (T3). Results: Treatment with reslizumab achieved complete asthma control in 40% of the 208 included SEUA patients and led to a significant reduction in exacerbations (from 3.0; IQR: 2.0-4.0 at V0 to 0.0; IQR: 0.0-0.0 at V2), maintenance OCS use (from 54.8% (95% CI: 48.0-61.6 at T0 to 18.5% (95% CI: 12.5-24.5 at T2) and a meaningful improvement in symptoms in the entire treated population: ACT increased from 12.8 ± 4.5 at V0 to 20.0 ± 5.1 at V2 (p < 0.001). Most of the improvement achieved at 12 months was obtained at 4-6 months. The retention (continuation) rate of reslizumab was 75% through 2 years (95CI%: 1.9-2.1). Overall, reslizumab showed an adequate safety profile. Conclusion: Reslizumab is an effective therapy for SEUA with adequate safety profile in real-life conditions.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-01
2022
2022-01-01
2024
2024-10-04
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/23389
url https://hdl.handle.net/20.500.12105/23389
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Dove Medical Press
publisher.none.fl_str_mv Dove Medical Press
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421669998657536
score 15.812455

Similares en LA Referencia